Literature DB >> 17601680

Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer.

Wilson Marhin1, Elaine Wai, Scott Tyldesley.   

Abstract

PURPOSE: To determine whether fraction size affects the risk of cardiac mortality in women treated with adjuvant radiotherapy (RT) for left-sided breast cancer. METHODS AND MATERIALS: A population-based retrospective study of women with a diagnosis of localized breast cancer treated with adjuvant RT in British Columbia from 1984 to 2000. Cases were identified from the British Columbia Cancer Agency database. Overall and cardiac-specific survival were compared for women treated with RT for left- vs. right-sided breast cancer. We analyzed the impact of age (<or=60 vs. >60 years) at diagnosis and RT fraction size (<or=2 vs. >2 Gy) on risk of fatal cardiac events.
RESULTS: We identified 3,781 women with left-sided and 3,666 women with right-sided breast cancer who received adjuvant RT. Median follow-up was 7.9 years. There were 52 vs. 47 breast cancer deaths in women treated for left- and right-sided breast cancer, respectively. There was no significant difference in cardiac mortality for women <or=60 or >60 years of age who received adjuvant RT for left-sided vs. right-sided cancer. There was no difference in cardiac mortality for women who received adjuvant RT with fraction sizes <or=2 vs. >2 Gy for left- or right-sided cancer.
CONCLUSIONS: There was no evidence for increased risk of cardiac mortality in women treated with adjuvant RT after a median follow-up of 7.9 years in our cohort. Hypofractionated adjuvant RT regimens did not significantly increase the risk of cardiac mortality.

Entities:  

Mesh:

Year:  2007        PMID: 17601680     DOI: 10.1016/j.ijrobp.2007.03.033

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  [Does hypofrantionated radiotherapy for breast cancer increase cardiac mortality within 20 years?].

Authors:  Juliane Rieber; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2014-08       Impact factor: 3.621

Review 2.  Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis.

Authors:  Partha Sardar; Amartya Kundu; Saurav Chatterjee; Anju Nohria; Ramez Nairooz; Sripal Bangalore; Debabrata Mukherjee; Wilbert S Aronow; Carl J Lavie
Journal:  Clin Cardiol       Date:  2016-11-02       Impact factor: 2.882

3.  Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population.

Authors:  L M Boerman; A J Berendsen; P van der Meer; J H Maduro; M Y Berger; G H de Bock
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

Review 4.  [Is cardiotoxicity still an issue after breast-conserving surgery and could it be reduced by multifield IMRT?].

Authors:  Frank Lohr; Felix Heggemann; Theano Papavassiliu; Mostafa El-Haddad; Oliver Tomé; Dietmar Dinter; Barbara Dobler; Uta Kraus-Tiefenbacher; Martin Borggrefe; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

5.  A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer.

Authors:  Sea-Won Lee; Yeon-Joo Kim; Kyung Hwan Shin; Kyubo Kim; Eui Kyu Chie; Wonshik Han; Seock-Ah Im; So-Youn Jung; Keun Seok Lee; Eun Sook Lee
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

6.  Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries.

Authors:  Katherine E Henson; Paul McGale; Sarah C Darby; Max Parkin; Yaochen Wang; Carolyn W Taylor
Journal:  Int J Cancer       Date:  2020-03-04       Impact factor: 7.396

7.  Can cutaneous telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer?

Authors:  G A Tanteles; J Whitworth; J Mills; I Peat; A Osman; G P McCann; S Chan; J G Barwell; C J Talbot; R P Symonds
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.